Overview

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Status:
Completed
Trial end date:
2021-03-11
Target enrollment:
Participant gender:
Summary
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Puma Biotechnology, Inc.
United States Department of Defense
Treatments:
Estradiol
Fulvestrant
Trastuzumab